'Upheavals' In Store As India Set To Mandate Marketing Code
Executive Summary
India's uniform code for pharmaceuticals marketing practices, so far voluntary in nature, appears to be on course to becoming "statutory" and "mandatory", signaling some potential short-term turbulence in the growing domestic market.
You may also be interested in...
Indian Policy Shifts Could Force Firms To Abandon 'Second Brand' Strategies
India’s new draft pharmaceutical policy proposes a raft of radical changes that have left industry jittery and could force a significant realignment in the operations of foreign and local firms. Second brand strategies and widespread licensing-out of manufacturing are no longer favored, and a 'one company – one drug – one brand name – one price' thrust are among the key changes proposed.
Indian Policy Shifts Could Force Firms To Abandon 'Second Brand' Strategies
India’s new draft pharmaceutical policy proposes a raft of radical changes that have left industry jittery and could force a significant realignment in the operations of foreign and local firms. Second brand strategies and widespread licensing-out of manufacturing are no longer favored, and a 'one company – one drug – one brand name – one price' thrust are among the key changes proposed.
India Pharma 2017: 3Cs And D (Disruption)?
2017 is predicted to be action-packed for the Indian pharmaceutical industry. Compliance-related issues, consolidation, a potential pick-up in collaborations between innovator and local firms, and activity around Indian biosimilars on the global stage, are just some of the things to keep an eye out for. Meanwhile, India’s demonetization move and the Trump presidency will be reminders to expect the unexpected, say experts.